|
Market Closed -
NYSE
00:03:30 03/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 261.72 USD | +0.67% |
|
-0.45% | +14.54% |
| 09-01 | Global pharma companies that have publicly announced Trump drug pricing agreements | RE |
| 08-27 | AbbVie Seeks EU Approval for Subcutaneous Skyrizi Induction in Crohn's Disease | MT |
| Market Cap | 462B 399B 376B 342B 640B 43,689B 645B 4,450B 1,727B 22,337B 1,737B 1,699B 73,376B | P/E 2026 * |
33.4x | P/E 2027 * | 24.7x |
|---|---|---|---|---|---|
| Enterprise Value | 523B 451B 425B 387B 724B 49,403B 729B 5,032B 1,953B 25,258B 1,964B 1,921B 82,973B | EV / Sales 2026 * |
7.74x | EV / Sales 2027 * | 6.99x |
| Free-Float |
95.71% | Yield 2026 * |
2.62% | Yield 2027 * | 2.75% |
Last Transcript : AbbVie Inc.
| 1 day | +0.67% | ||
| 1 week | -0.45% | ||
| Current month | +2.07% | ||
| 1 month | +4.30% | ||
| 3 months | +21.50% | ||
| 6 months | +11.72% | ||
| Current year | +14.54% |
| 1 week | 252.33 |  | 262.97 |
| 1 month | 241.2 | | 266.96 |
| Current year | 190.75 | | 267.47 |
| 1 year | 190.75 | | 267.47 |
| 3 years | 135.85 | | 267.47 |
| 5 years | 105.56 | | 267.47 |
| 10 years | 55.06 | | 267.47 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Michael
CEO | Chief Executive Officer | 55 | 01/07/2024 |
Scott Reents
DFI | Director of Finance/CFO | 59 | 23/06/2022 |
Linda Ray
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 65 | 01/01/2013 |
William Burnside
BRD | Director/Board Member | 74 | 01/01/2013 |
Ed Rapp
BRD | Director/Board Member | 69 | 01/01/2013 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 14/08/26 | Exercice | Executive/Senior Manager | 98,130 | 0.0056% | ||
| 30/06/26 | Free | Director | 62 | 0.0000% | ||
| 30/06/26 | Free | Director | 134 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.67% | -0.45% | +23.50% | +76.60% | 459B | |
| +0.01% | -2.47% | +57.79% | +108.23% | 1,034B | |
| +1.48% | +1.93% | +54.56% | +71.49% | 654B | |
| +0.49% | -5.19% | +33.28% | +34.59% | 343B | |
| +0.27% | +3.26% | +29.76% | +46.97% | 307B | |
| +0.12% | -2.11% | +0.60% | +11.93% | 251B | |
| +1.08% | +0.57% | +54.34% | +72.51% | 237B | |
| +2.64% | -1.08% | -15.85% | -53.64% | 202B | |
| -0.21% | +1.03% | +32.74% | +95.19% | 186B | |
| +1.65% | +2.54% | +16.17% | -18.89% | 163B | |
| Average | +0.62% | -1.02% | +28.69% | +44.50% | 383.43B | |
| Weighted average by Cap. | +0.59% | -1.14% | +37.89% | +63.65% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 67.58B 58.31B 54.92B 50.04B 93.54B 6,384B 94.24B 650B 252B 3,264B 254B 248B 10,723B | 73.52B 63.43B 59.75B 54.44B 102B 6,945B 103B 707B 275B 3,551B 276B 270B 11,664B |
| Net income | 13.86B 11.96B 11.27B 10.26B 19.18B 1,309B 19.33B 133B 51.76B 669B 52.05B 50.91B 2,199B | 18.91B 16.32B 15.37B 14B 26.18B 1,787B 26.37B 182B 70.62B 913B 71.02B 69.47B 3,001B |
| Net Debt | 60.49B 52.19B 49.16B 44.79B 83.72B 5,714B 84.35B 582B 226B 2,922B 227B 222B 9,597B | 51.66B 44.57B 41.98B 38.25B 71.5B 4,880B 72.04B 497B 193B 2,495B 194B 190B 8,196B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/09/26 | $261.72 | +0.67% | 4,225,237 |
| 01/09/26 | $259.99 | +1.39% | 3,866,739 |
| 31/08/26 | $256.42 | +0.37% | 4,315,487 |
| 28/08/26 | $255.48 | -1.03% | 3,224,862 |
| 27/08/26 | $258.15 | -1.81% | 4,764,797 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ABBV Stock
Select your edition
All financial news and data tailored to specific country editions
